摘要:
The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
摘要:
The invention relates to human cells which are capable, on the basis of an activation of the endogenous human EPO gene, of producing EPO in a sufficient amount and purity to make possible a cost-effective production of human EPO as a pharmaceutical preparation. The invention furthermore relates to a method for the preparation of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO in human cells, and a method for the large technical production of EPO in human cells.
摘要:
The new type II restriction endonuclease SexAI has the following recognition sequence and preferably cleaves at the cleavage site defined by the mark: ##STR1## It is preferably obtainable from microorganisms of the genus Streptomyces.
摘要:
An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between CH1 and CH2 and/or in the second inter-domain region at amino acid position 327-331 between CH2 and CH3 has advantageous properties for the treatment of inflammatory diseases.
摘要:
An antibody specifically binding to human thymic stromal lymphopoietin receptor (TSLPR), characterized in comprising as heavy chain variable domain CDR regions a CDR1 region of SEQ ID NO:2 or 17, a CDR2 region of SEQ ID NO:3 or 10, and CDR3 region of SEQ ID NO:4, and as light chain variable domain CDR regions a CDR1 region of SEQ ID NO:6 or 12, a CDR2 region of SEQ ID NO:7, 13 or 15, and a CDR3 region of SEQ ID NO:8. is useful for the treatment of immunological diseases.
摘要翻译:特异性结合人胸腺基质淋巴细胞生成素受体(TSLPR)的抗体,其特征在于,其包含SEQ ID NO:2或17的CDR1区,SEQ ID NO:3或10的CDR2区和CDR3区的重链可变结构域CDR区 SEQ ID NO:4的区域,以及轻链可变结构域CDR区SEQ ID NO:6或12的CDR1区,SEQ ID NO:7,13或15的CDR2区和SEQ ID NO:4的CDR3区 :8。 可用于治疗免疫疾病。
摘要:
A method for the production of the α-chain of hepatocyte growth factor or an N-terminal fragment thereof (NK polypeptide) by expression of a nucleic acid encoding said NK polypeptide in a microbial host cell, isolating inclusion bodies containing said NK polypeptide in denatured form, solubilization of the inclusion bodies and naturation of the denatured NK polypeptide, which is characterized in that in said nucleic acid at least one of the codons of amino acids selected from the group consisting of codons at positions 33, 35 and 36 is CGT, results in an improved expression yield.
摘要:
An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between CH1 and CH2 and/or in the second inter-domain region at amino acid position 327-331 between CH2 and CH3 has advantageous properties for the treatment of inflammatory diseases.
摘要:
The invention concerns a method for the introduction of a foreign DNA into the genome of a target cell by homologous recombination as well as for the homologous recombination of suitable DNA constructs.
摘要:
The present invention generally relates to novel bispecific antigen binding molecules. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
摘要:
An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between CH1 and CH2 and/or in the second inter-domain region at amino acid position 327-331 between CH2 and CH3 has advantageous properties for the treatment of inflammatory diseases.